Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
|
BR |
Oncoclinicas do Brasil Servicos Medicos SA
Oncoclínicas do Brasil Serviços Médicos SA operates as a holding company, which engages in oncology clinics through the health care segment. The company is headquartered in Sao Paulo, Sao Paulo. The company went IPO on 2021-08-10. The firm provides of medical services focused on Oncology. The Company, since its foundation, in addition to acting directly in the treatment of cancer patients, has dedicated itself to the study and identification of the appropriate therapy opportunities for patients and the growth trends in the sector. The firm holds interest in a number of subsidiaries, such as Centro de Quimioterapia Antiblastica e Imunoterapia SA, Centro Mineiro de Infusoes SA, and Centro Paulista de Oncologia SA.
Oncoclínicas do Brasil Serviços Médicos SA operates as a holding company, which engages in oncology clinics through the health care segment. The company is headquartered in Sao Paulo, Sao Paulo. The company went IPO on 2021-08-10. The firm provides of medical services focused on Oncology. The Company, since its foundation, in addition to acting directly in the treatment of cancer patients, has dedicated itself to the study and identification of the appropriate therapy opportunities for patients and the growth trends in the sector. The firm holds interest in a number of subsidiaries, such as Centro de Quimioterapia Antiblastica e Imunoterapia SA, Centro Mineiro de Infusoes SA, and Centro Paulista de Oncologia SA.
Strategic reset: New CEO Carlos Gil said the company is simplifying its structure, tightening financial discipline, and refocusing on its core outpatient oncology business.
Revenue pressure: Full-year revenue fell 7% to BRL 6.4 billion, mainly because the company exited or reduced business with payers that created poor cash cycles, especially Unimed-related accounts.
Liquidity strain: Management said liquidity was hit by more than BRL 1.2 billion from two large events: unpaid receivables from Unimed Ferj and the loss of cash tied to Banco Master’s liquidation.
Balance-sheet repair: A BRL 1.4 billion debt-to-equity conversion helped reduce net debt to BRL 2.9 billion from BRL 4.1 billion, but covenant pressure remains.
Asset sales: The company is continuing to sell hospital assets, with UMC already sold, Vila da Serra in final negotiation, and the Marcos Moraes hospital back in portfolio after a buyer backed out.
Outlook tone: Management emphasized that the priority now is preserving operations at the outpatient clinics while negotiations with creditors and asset monetization continue.
